iRhythm Technologies, Inc. (NASDAQ:IRTC) Stock Position Raised by Amundi

Amundi boosted its holdings in iRhythm Technologies, Inc. (NASDAQ:IRTC - Free Report) by 8.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 102,908 shares of the company's stock after acquiring an additional 7,941 shares during the period. Amundi owned about 0.33% of iRhythm Technologies worth $9,570,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of IRTC. R Squared Ltd bought a new stake in shares of iRhythm Technologies in the 4th quarter worth approximately $45,000. Van ECK Associates Corp lifted its stake in iRhythm Technologies by 41.3% in the fourth quarter. Van ECK Associates Corp now owns 554 shares of the company's stock valued at $50,000 after buying an additional 162 shares during the last quarter. Quarry LP acquired a new position in shares of iRhythm Technologies during the third quarter valued at $59,000. Nisa Investment Advisors LLC grew its position in shares of iRhythm Technologies by 166.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,037 shares of the company's stock worth $94,000 after acquiring an additional 648 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of iRhythm Technologies in the 3rd quarter worth about $119,000.

iRhythm Technologies Price Performance

Shares of NASDAQ IRTC traded down $2.04 during mid-day trading on Tuesday, reaching $101.66. The company had a trading volume of 216,047 shares, compared to its average volume of 460,216. The company has a 50-day moving average price of $106.98 and a two-hundred day moving average price of $87.96. The stock has a market cap of $3.19 billion, a PE ratio of -27.93 and a beta of 1.36. The company has a current ratio of 6.27, a quick ratio of 6.12 and a debt-to-equity ratio of 9.00. iRhythm Technologies, Inc. has a 1-year low of $55.92 and a 1-year high of $128.52.

Remove Ads

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.30. The firm had revenue of $164.33 million for the quarter, compared to analysts' expectations of $158.30 million. iRhythm Technologies had a negative return on equity of 118.83% and a negative net margin of 19.14%. On average, equities analysts anticipate that iRhythm Technologies, Inc. will post -1.98 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on IRTC shares. Canaccord Genuity Group boosted their target price on shares of iRhythm Technologies from $125.00 to $152.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Truist Financial boosted their price objective on iRhythm Technologies from $111.00 to $145.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. StockNews.com raised iRhythm Technologies from a "sell" rating to a "hold" rating in a report on Monday, February 24th. Needham & Company LLC lifted their target price on iRhythm Technologies from $125.00 to $138.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Finally, The Goldman Sachs Group increased their price target on iRhythm Technologies from $91.00 to $124.00 and gave the stock a "neutral" rating in a research note on Monday, February 24th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $119.73.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.